Quick Facts

• Therapeutic Domain: Acute viral respiratory infections.
• Primary Indications: Influenza A and B.
• Additional Uses: Adenovirus, parainfluenza, and respiratory syncytial virus (RSV) infections.
• Goal of Therapy: Supports symptom management and viral clearance.

Ингавирин (Ingavirin) is indicated for addressing several types of acute viral respiratory infections, including both Influenza A and Influenza B. This medication is utilized in the management of the symptoms associated with these viral illnesses.

Its therapeutic application extends to other acute viral infections of the respiratory tract, such as infections caused by the Adenovirus, Parainfluenza virus, and the Respiratory Syncytial Virus (RSV). The drug is employed to aid in the recovery process from these conditions and to support the reduction of the viral load in the body.

Ingavirin is part of a therapeutic regimen intended to support the body’s response to the infection and is typically initiated soon after the onset of symptoms. The use of the agent is associated with facilitating the alleviation of associated symptoms.

The primary function within its approved therapeutic domains is to help address the progression of the viral infection and contribute to a more timely return to health.

Eligibility Profile: Who Can and Cannot Use Ингавирин?

Regulatory documents strictly define the patient groups eligible for Ингавирин (90 mg capsule formulation) and establish clear contraindications.

Category	Official Regulatory Status
Allowed Population	Adults aged 18 years and older are the approved group for use.
Age/Physiological Status	Use is strictly prohibited (contraindicated) in children and adolescents under 18 years old, pregnant women, and breastfeeding women (lactation).
Hypersensitivity	Contraindicated for individuals with known sensitivity to the active ingredient, Imidazolyl Ethanamide Pentandioic Acid, or any excipients.
Comorbidity Restriction	Contraindicated in patients with lactose deficiency, lactose intolerance, or glucose-galactose malabsorption due to the capsule's excipient content.
Special Population Note	Safety and efficacy have not been established in patients with severe, decompensated chronic cardiovascular, renal, or hepatic diseases.

These classifications define the population for whom the medicine is intended. The profile clearly outlines non-eligible groups based on age, physiological status, and pre-existing intolerances, serving as the official regulatory basis for use.

Interactions with other medicines and products

The official regulatory documentation for Ингавирин (Imidazolyl Ethanamide Pentandioic Acid) indicates that no specific drug-drug interactions were established or described following formal clinical investigations. The interaction profile is largely characterized by a lack of documented pharmacokinetic or pharmacodynamic effects with commonly co-administered products.

Interaction Status and Restrictions

Interaction Type	Regulatory Finding
Documented Drug-Drug Interactions	None established in official prescribing information.
Metabolic/Transporter Interactions	No formal interactions via CYP enzymes or drug transporters are described.
Co-administration with Symptomatic Agents	Co-administration with products used for symptomatic relief of acute respiratory viral infections (e.g., antipyretics, expectorants) has not resulted in documented adverse interactions.
Food and Timing Requirements	Administration is independent of food intake; no timing separation is mandated.
Antiviral Combinations	The official regulatory instruction states that the concurrent use with other antiviral drugs is not recommended and is a specific restriction.

Official Regulatory Summary

The medicine's regulatory summary primarily notes the high compatibility with supportive care medicines for ARVIs. The absence of specific documented interactions means no timing separation is required for meals or symptomatic medications. The primary constraint is the official cautionary statement against combining it with other antiviral preparations.

Ингавирин (imidazolyl ethanamide pentandioic acid) functions through a complex, multi-target mechanism within host cells. Primarily, it acts by inhibiting viral replication via interference with the nuclear transport of viral nucleoproteins. This antiviral interaction disrupts a critical step required for the transcription and multiplication of viral progeny.

In parallel, the compound modulates the host immune response. It is a non-interferon inducer that enhances the synthesis of Interferon-alpha and Interferon-beta receptors (IFNAR), thereby increasing cellular sensitivity to endogenous interferon signaling. Furthermore, Ингавирин is an activator of Toll-like Receptor (TLR) and RIG-I-like Receptor (RLR) signaling pathways, specifically TLR3/7/8/9 and RIG1/MDA5. Activation of these pattern recognition receptors stimulates the expression of downstream signaling factors, including MAVS and NFκB1.

This downstream cascade results in the heightened expression of antiviral effector proteins such as Protein Kinase R (PKR) and Myxovirus resistance protein A (MxA), effectively counteracting pathogen-mediated suppression of the interferon system. At the system level, this pharmacodynamic profile leads to the modulation of innate and adaptive immune responses and influences the expression of inflammatory mediators.

Instruction Map: How to use Ингавирин — Administration Guidelines

Field	Instruction
Route of administration	Oral (by mouth).
Dosing schedule	The standard adult dose for both treatment and prophylaxis is 90 mg once daily.
Timing in relation to meals (if applicable)	Administration is generally independent of food intake, allowing the medicine to be taken with or without meals.
Preparation requirements (if applicable)	Capsules are typically swallowed whole. For younger pediatric patients using lower strengths, the contents of the capsule may be dissolved in a small amount of water or juice for oral delivery.
Age-group administration rules	Dosing is adjusted by age: adolescents (13 years and older) typically use a lower 60 mg dose once daily. Specific regimens are defined for children down to 3 years of age, often utilizing a lower capsule strength or oral solution.
Missed-dose rules	Specific instructions for managing a missed dose are not universally detailed.
Special procedural conditions	The standard course of treatment is a fixed short-term duration, typically lasting 5 to 7 consecutive days.

---

Instruction Classifications (High-Level)

Classification	Description
Administration method type	Oral.
Frequency pattern	Daily (Once per 24 hours).
Use-context constraints	Fixed-duration course, age-adjusted dosing required for children, and administration independent of mealtimes.

---

Resulting Procedural Structure

Instructional step sequence:

• Take the medicine once per day, using the prescribed capsule strength or oral solution.
• Maintain the consistent daily dosing schedule for the fixed duration of the treatment course (e.g., 5 to 7 days).
• Adjustments to the dose are required based on the patient's age and may be authorized for initial dosing in cases of acute presentation.

Connection to the overall use protocol: The instructions establish the use of this medicine as a standardized, short-term, once-daily oral treatment regimen. This structure dictates a usage pattern defined by a fixed total duration and consistent daily frequency. The primary variations in use are determined by the specific age group of the patient, which requires the use of corresponding dosage strengths.

Ингавирин: Recent Clinical Evidence

---

Evidence for Treatment of Acute Viral Respiratory Infections (ARVIs)

The molecule was studied in research exploring acute conditions, such as uncomplicated influenza and other acute respiratory viral infections (ARVIs). These studies were typically short-term, randomized, placebo-controlled trials (RCTs). Researchers primarily examined the time required for a return to normal body temperature, the duration until the resolution of specific symptoms (e.g., headache, malaise, cough), and monitored the measured frequency of complications in the observed populations. Findings describe patterns observed in the studies related to the measured outcomes.

---

Comparative Research and Populations Studied

Some research designs featured comparative elements, evaluating the molecule against a placebo and other approved antiviral agents. The research examined differences in measured outcomes between the study group, the placebo group, and comparator groups. The existing evidence landscape was evaluated across a broad range of ages, including infants (starting at six months), children, adolescents, and adults. However, studies required a clinically established diagnosis of uncomplicated ARVI, meaning research did not include those with signs of severe or complicated disease, such as viral pneumonia or infectious-toxic shock.

---

Research on Post-Exposure Prophylaxis

Ингавирин was studied for post-exposure prophylaxis, or preventative use, in specific research scenarios focused on healthy adults with known recent contact with a sick person. The primary outcome monitored was the incidence rate, which tracked illness development in the observed population. Research examined the patterns of illness development over defined time intervals, providing context but not individual predictions regarding whether a person who has been exposed may develop the illness.

---

Research Gaps and Areas of Uncertainty

The time intervals for observation in the key clinical trials were limited, typically short-term (up to three weeks). Because of this short duration, long-term effects are not fully established, and evidence is limited regarding sustained durability of recovery. The research highlights that results apply only to the populations studied. Studies consistently excluded patients with severe or complicated courses, meaning data for certain high-risk groups with advanced comorbidities remain insufficient, and comparative evidence for these complex subgroups is uncertain.

Key Studies & References

1. INGAVIRIN: Imidazolyl ethanamide pentandioic acid - Ginas Substance Record

Common questions about Ингавирин (FAQ)

---

Q: What is Ingavirin (Ингавирин)?

A: Ingavirin is a pharmaceutical agent with the active ingredient imidazolylethanamide pentandioic acid. It is classified as an antiviral drug. It has been approved for use in the treatment of influenza and other acute respiratory viral infections in specific regions.

---

Q: How is Ingavirin taken?

A: Ingavirin is taken orally (by mouth). Specific instructions regarding the amount, frequency, and duration of use should be provided by a qualified healthcare professional. Always follow the administration guidance provided by your prescriber and the official patient information leaflet.

---

Q: Can Ingavirin be used to treat COVID-19?

A: Ingavirin is indicated for the treatment of influenza and other acute respiratory viral infections as approved by local regulatory bodies. Its use in the treatment of COVID-19 is not standardized and is not listed as an approved indication in many major health authorities. Any use for conditions other than its approved indications should be discussed with a healthcare provider, and should align with current medical guidelines.

---

Q: Is Ingavirin safe for children?

A: The use of Ingavirin is restricted to adults and children who meet the minimum age and weight requirements specified in the official prescribing information. The safety and efficacy in children under the specified age have not been established in all jurisdictions.

---

Q: Does Ingavirin cause side effects?

A: Like all pharmaceutical products, Ingavirin may be associated with side effects. Clinical data indicates that the drug is generally observed to be well-tolerated in many patients. Common side effects reported may include allergic reactions or digestive tract disturbances. It is important to review the patient information leaflet for a full list of known side effects and to consult a healthcare professional immediately if you experience any adverse reactions.

---

Q: Can Ingavirin interact with other medications?

A: As with many medications, there is a possibility that Ingavirin could interact with other drugs, which may alter the effect of either medication. It is necessary to inform your healthcare provider of all prescription drugs, over-the-counter medications, and supplements you are currently taking before starting Ingavirin.

How to Store and Dispose of Ингавирин (Ingavirin)

All storage and disposal requirements for Ингавирин capsules are defined by regulatory labeling to maintain quality and safety.

Storage Requirements

The product must be stored at a temperature not exceeding 25 C. It is mandatory to store the capsules in their original packaging, in a dry place, and in a location protected from light. The medicine has an official shelf-life of 3 years when stored correctly.

Critically, the product must be kept strictly out of the reach and sight of children to prevent accidental ingestion.

Disposal Instructions

To protect the environment, unused or expired Ингавирин must not be disposed of via sewage or wastewater. Disposal must be carried out in accordance with local legal requirements for pharmaceutical waste, which often involves returning the product to a pharmacy or designated collection point.